Gastrointestinal (GI) bleeding is a sign of an illness in which the gastrointestinal system bleeds. The bleeding could occur anywhere in the gastrointestinal system, including the large intestine, anus, esophagus, small intestine, rectum, and stomach. The main type of products used in gastrointestinal bleeding treatment devices market are endoscopic mechanical devices, endoscopic thermal devices, and others. Endoscopic mechanical devices are used in the management of GI arterial bleeding.  These include hemostatic clips, also known as through-the-scope (TTS) clips, endoscopic detachable snare ligation (EDSL) devices, endoscopic suturing, and over-the-scope clips (OTSC), and will be reviewed for their technology use and clinical application. The gastrointestinal bleeding treatment devices market is also segmented by GI tract division into the lower GI tract and upper GI tract and is used in hospitals or clinics, ambulatory surgical centers, others. The gastrointestinal bleeding treatment market research report is one of a series of new reports from The Business Research Company that provides gastrointestinal bleeding treatment market statistics, including gastrointestinal bleeding treatment industry global market size, regional shares, competitors with a gastrointestinal bleeding treatment market share, detailed gastrointestinal bleeding treatment market segments, market trends and opportunities, and any further data you may need to thrive in the gastrointestinal bleeding treatment industry. This gastrointestinal bleeding treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global gastrointestinal bleeding treatment devices market size grew from $0.78 billion in 2022 to $0.83 billion in 2023 at a compound annual growth rate (CAGR) of 6.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The gastrointestinal bleeding treatment devices market size is expected to grow to $1.03 billion in 2027 at a CAGR of 5.6%. The rise in the incidences of upper gastrointestinal bleeding is likely to contribute to the growth of the gastrointestinal bleeding treatment devices market during the forecast period. The upper gastrointestinal (GI) bleeding occurs in the esophagus, the stomach, or the upper part of the small intestine and can be caused due to peptic ulcers, esophagitis, enteritis, gastritis, cancer, and other reasons.  For instance, according to the National Institute for Health and Care Excellence, in the UK the incidence of acute upper GI bleeding ranges from 84-172 per 100,000 of the population per year. Furthermore, as per the study published by the International Journal of Surgery Global Health in May 2020, the incidence of acute upper GI bleeding in the Western world recorded to be 103 cases per 100,000 adults annually.  Therefore, the rise in the incidences of upper gastrointestinal bleeding propels the growth of the gastrointestinal bleeding treatment devices market. The increasing number of product approvals is the key trend gaining popularity in the gastrointestinal bleeding treatment devices market. Key players in the market are focusing on product approvals to maintain a comparative advantage over competitors in the industry. For example, in February 2021, EndoClot Plus Inc., a US-based company developing medical devices to meet the needs of the GI professional announced U.S. Food and Drug Administration (FDA) approval for EndoClot Polysaccharide Hemostatic System (EndoClot PHS), which is an advanced product that will assist Gastroenterologists to stop bleeding quickly and effectively. EndoClot PHS is a one-time-use device that consists of a starch-based powder hemostat that is applied directly to the bleeding location using a flexible endoscope. In January 2021, Olympus Corporation, a Japan-based company offering solutions for the effective treatment of gastrointestinal bleeding, announced a collaboration with Hitachi Ltd for five-year. Under this collaboration, the companies will work together to develop Endoscopic Ultrasound Systems (EUS), which are used to treat digestive diseases and assess the stage of cancer in the bronchus, liver, pancreas as well as in minimally invasive care, thereby contributing to medical treatment. Hitachi Ltd is a Japanese multinational conglomerate company offering gastrointestinal diagnoses solutions. Major players in the gastrointestinal bleeding treatment devices market are CONMED, Boston Scientific Corporation, US Medical Innovations, Ovesco Endoscopy AG, Olympus Corporation, Cook Medical, Erbe Elektromedizin GmbH, Steris PLC, and Pfizer Inc. North America was the largest region in the gastrointestinal bleeding treatment devices market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal bleeding treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the gastrointestinal bleeding treatment devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The gastrointestinal bleeding treatment devices market consists of sales of thermal therapy, multipolar electrocoagulation probe, heater probe, hemostatic foreceps, and argon plasma coagulation. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global gastrointestinal bleeding treatment devices market is segmented - 1) By Product: Endoscopic Thermal Devices, Other Products 2) By GI Tract Division: Upper GI Tract, Lower GI Tract 3) By End User: Hospitals Or Clinics, Ambulatory Surgical Centers, Other End-users

Gastrointestinal devices are used for the diagnosis and treatment of medical conditions related to the digestive system or the gastrointestinal tract. The main product types of gastrointestinal devices are GI videoscopes, biopsy devices, endoscopic retrograde cholangiopancreatography devices (ERCP), capsule endoscopy, endoscopic ultrasound, endoscopic mucosal resection (EMR), hemostasis devices, and others. Endoscopic retrograde cholangiopancreatography, or ERCP refers to a process of diagnosing and treating problems in the liver, gallbladder, bile ducts, and pancreas. The various sales channels are online retailing, medical stores, and brand outlets. These are used in hospitals, clinics, dialysis centres, and ambulatory surgical centres. The gastrointestinal devices market research report is one of a series of new reports from The Business Research Company that provides gastrointestinal devices market statistics, including gastrointestinal devices industry global market size, regional shares, competitors with a gastrointestinal devices market share, detailed gastrointestinal devices market segments, market trends and opportunities, and any further data you may need to thrive in the gastrointestinal devices industry. The gastrointestinal devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global gastrointestinal devices market grew from $10.05 billion in 2022 to $10.61 billion in 2023 at a compound annual growth rate (CAGR) of 5.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The gastrointestinal devices market is expected to grow from $13.7 billion in 2027 at a CAGR of 6.6%. The increasing prevalence of gastrointestinal diseases contributed to the growth of the gastrointestinal devices market. Gastrointestinal diseases include irritable bowel syndrome, hemorrhoids, perianal abscesses, colon polyps, and cancer, among others. According to the Endoscopy Centre, every year, 62 million Americans are diagnosed with any of the digestive disease, and 2% to 6% or an estimated three lakhs to 5 lakhs Americans suffer from inflammatory bowel disease (IBD). According to the American College of Gastroenterology estimates, 10-15% of the adult population in the USA suffer from irritable bowel syndrome (IBS) symptoms. The increased prevalence of gastrointestinal diseases increased the demand for gastrointestinal devices to treat patients, thereby driving the market growth. High healthcare costs for treating gastrointestinal disease restrain the gastrointestinal devices market. According to the NEJM Journal Watch, a sister publication of the New England Journal of Medicine, the overall healthcare expenditure for the gastrointestinal disease is around $136 billion annually, which is more than heart disease healthcare expenditure ($113 billion), trauma expenditure ($103 billion), mental health expenditure ($99 billion), indicating the high expenses involved in treating gastrointestinal disease. Moreover, a database analysis by American Gastroenterological Association states that patients with inflammatory bowel diseases (IBDs), chronic liver diseases (CLDs), functional gastrointestinal disorders (FGIDs), gastrointestinal hemorrhage are hospitalized at least once and are high-need and high-cost patients contributing disproportionately to hospitalization costs. In this context, they are the ones who are accessing inpatient services and need immense care due to functional limitations increasing the expenditure. The high healthcare expenditure for gastrointestinal disease forces the majority population to refrain from receiving treatment in non-emergency cases, which negatively impacts the growth of the gastrointestinal devices market. Single-use disposable endcap of duodenoscope is increasingly being used to prevent contamination during endoscopic retrograde cholangiopancreatography (ERCP) procedures. Single-use disposable cap controls the infection and preserves the duodenoscope optics. The USFDA recommended that hospitals and clinics shift from reusable duodenoscopes to disposable parts duodenoscopes. The USFDA also approved the duodenoscope model featuring the disposable parts such as the Olympus TJF-Q190V Duodenoscope in January 2020 and Ambu® aScope™ Duodenoscope in July 2020. Olympus TJF-Q190V duodenoscope is used to perform the ERCP procedure with less risk of contamination due to the disposable distal endcap. For instance, in 2020, Olympus Corporation has announced the acquisition of Arc Medical Design Limited (Arc Medical Design), a subsidiary of Norgine B.V. This acquisition helps Olympus’ commitment to enlarging its offering in gastrointestinal therapeutic devices and the improvement of advanced colonoscopy tools. Norgine is a European-based specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Major players in the gastrointestinal devices market are Boston Scientific, Medtronic, Fujifilm Holdings Corporation, CONMED Corporation, Stryker Corporation, Johnson & Johnson, Olympus, Cook Group, Becton, Dickinson, and Company, and B. Braun Melsungen. North America was the largest region in the gastrointestinal devices market in 2022. Asia-Pacific was the second largest region in the global gastrointestinal devices market report. The regions covered in the global gastrointestinal devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the gastrointestinal devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The gastrointestinal devices market consists of sales of instruments such as gastroscope, an enteroscope, and an ultrasound endoscope. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global gastrointestinal devices market is segmented - 1) By Product Type: GI Videoscopes, Biopsy Devices, Endoscopic Retrograde Cholangiopancreatography Devices (ERCP), Capsule Endoscopy, Endoscopic Ultrasound, Endoscopic Mucosal Resection (EMR), Hemostasis Devices, Other Product Types 2) By End Users: Hospitals, Clinics & Dialysis Centers, Ambulatory Surgical Center 3) By Sales Channel: Online Retailing, Medical Stores & Brand Outlet

Biosimilar therapeutic peptides refer to a peptide drug that is used in place of or in addition to peptide hormones when endogenous levels tend to decline. Therapeutic peptides that are biosimilar have applications in the treatment of cancer, metabolic, pulmonary, cardiovascular, and other illnesses. The two main types of biosimilar therapeutic peptides are innovative and generic. Biosimilar medications are frequently mistaken for generic drugs. Both are marketed as low-cost knockoffs of high-priced name-brand medications. The main distinction is that generics are duplicates of synthetic pharmaceuticals, whereas biosimilars are based on drugs that contain biological organisms as active components. The different routes of administration include the parenteral route, the transdermal route, and others and are used in cancer, cardiovascular disorders, central nervous system, metabolic disorders, infections, haematological disorders, gastrointestinal disorders, dermatology, and respiratory disorders. The biosimilar therapeutic peptides market research report is one of a series of new reports from The Business Research Company that provides biosimilar therapeutic peptides market statistics, including global market size, regional shares, competitors with a biosimilar therapeutic peptides market share, detailed biosimilar therapeutic peptides market segments, market trends, and opportunities, and any further data you may need to thrive in the biosimilar therapeutic peptides industry. This biosimilar therapeutic peptide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global biosimilar therapeutic peptides market grew from $1.21 billion in 2022 to $1.58 billion in 2023 at a compound annual growth rate (CAGR) of 30.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The biosimilar therapeutic peptides market is expected to grow from $3.9 billion in 2027 at a CAGR of 25.3%. The increasing ageing population is projected to surge the number of patients with chronic diseases, contributing to the biosimilar therapeutic peptides’ market's growth. Elderly people are more prone to various chronic diseases, which are surging the old age population rapidly across the world and is predicted to continue over the forecast period. According to the World Health Organization (WHO), the world’s population over the age of 60 is expected to reach 2 billion by the end of 2050. Moreover, according to the World Population Prospects, the number of people aged 80 and above is likely to increase from 143 million in 2019 to 426 million in 2050. Biosimilar therapeutic peptides are used for the treatment of various chronic diseases and cancers. The expected increase in the ageing population suffering from various chronic conditions will drive the biosimilar market. The long and costly drug approval process is expected to limit the growth of the biosimilar therapeutic peptide market over the upcoming years. The development, approval, and launch of new drugs is an expensive and prolonged procedure that includes expensive research stages. A new drug has to go through four phases of clinical trials and screening by the regulatory body, including the Food and Drug Administration (FDA) (USA), the Medicines and Healthcare Products Regulatory Agency (MHRA) (UK), and the Medicines and Healthcare Products Regulatory Agency (MHRA) (India). For instance, in September 2020, according to an article shared by Proclinical, a UK-based recruitment agency in the life sciences sector, the average cost to create a new drug is close to $4 billion, however, this cost might occasionally reach $10 billion. No other sector invests more in R&D than the semiconductor industry. According to a recent research, R&D costs are predicted to climb by 3% annually and surpass $203 billion by 2024, therefore, this trend is only projected to continue. Therefore, a long and costly drug approval process is anticipated to hinder the growth of the biosimilar therapeutic peptide market. During the forecast period, the biosimilar therapeutic peptides market is expected to witness growth in research collaborations as well as research funding approvals. Collaborations with other companies and organisations are being prioritised by key companies in order to improve research and development, expand product portfolios, and expand geographical reach.For instance, in January 2020, a UK-based biotechnology company focusing on developing a class of therapeutics based on its proprietary bicyclic peptide technology announced a collaboration with Cancer Research UK to develop BT7401, a new bicyclic immuno-oncology candidate. Cancer Research UK will fund and sponsor the development of a new candidate. In addition to this, Sapience Therapeutics, Inc., a US-based biotechnology company focused on the research & development of peptide therapeutics, announced a research collaboration with the University of Bath (UK) to develop and discover new therapeutic agents for oncology applications. Hence, research collaborations to develop new therapeutic peptides are a major trend in the market. In September 2020, Ligand Pharmaceuticals Incorporated, a US-based biopharmaceutical company, acquired Pfenex Inc. for an undisclosed amount. The acquisition would provide Ligand access to its proprietary protein expression technology. The transaction has the potential to have a materially beneficial scientific and financial impact on our business in the immediate and long terms. Pfenex would provide Ligand with a well-established, tested protein expression platform that would provide a great complement to our vital, exclusive drug discovery and formulation technologies. Pfenex Inc. is a US-based manufacturer of biosimilars, including teriparatide, ranibizumab, and pegfilgrastim. Major players in the biosimilar therapeutic peptides market are Eli Lilly, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc., Amgen Inc., AstraZeneca PLC., GlaxoSmithKline (GSK), Novartis AG, and Novo Nordisk A/S. North America was the largest region in the biosimilar therapeutics market in 2022. The Middle East is expected to be the fastest growing region in the global biosimilar therapeutic peptides market during the forecast period. The regions covered in the global biosimilar therapeutic peptides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the biosimilar therapeutic peptides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The biosimilar therapeutic peptides market consists of sales of pegfilgrastim, bevacizumab, and adalimumab. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global biosimilar therapeutic peptides market is segmented - 1) By Route Of Administration: Parenteral Route, Transdermal Route, Other Route Of Administrations 2) By Application: Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders 3) By Type: Innovative, Generic

Endoscopy devices and equipment are used to examine the interiors of organs, and the cavities of the body. These devices enable doctors to view the digestive tract on a screen and aid in the diagnosis of medical conditions. The main products of endoscopy devices and equipment are endoscopes, endoscopy operative devices, and endoscopy visualization systems. The endoscope is a lighted optical instrument that is used to get a deep look inside the body. An endoscope, which is rigid or flexible, is used to examine organs, like the throat or esophagus. The various applications involved are bronchoscopy, arthroscopy, laparoscopy, urology endoscopy, neuroendoscopy, gastrointestinal endoscopy, obstetrics/gynecology endoscopy, ENT endoscopy, and others that are used by various end-users such as hospitals, clinics, and others. The endoscopy devices and equipment market research report is one of a series of new reports from The Business Research Company that provides endoscopy devices and equipment market statistics, including endoscopy devices and equipment industry global market size, regional shares, competitors with a endoscopy devices and equipment market share, detailed endoscopy devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the endoscopy devices and equipment industry. This endoscopy devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global endoscopy devices and equipment market size will grow from $7.9 billion in 2022 to $8.5 billion in 2023 at a compound annual growth rate (CAGR) of 7.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The endoscopy devices and equipment market size is expected to grow to $10.94 billion in 2027 at a CAGR of 6.5%. The rise in incidence and prevalence rates of gastrointestinal (GI) diseases is driving the endoscopy devices and equipment market. The increasing incidence of gastrointestinal diseases such as colorectal cancer, gastroesophageal reflux disease, ulcerative colitis (UC), inflammatory bowel disease (IBD), and Crohn's disease (CD) are supporting the endoscopy devices and equipment market. The endoscopy devices are used in performing non-invasive or minimally invasive surgical procedures to treat life-threatening diseases. The Asian countries have the highest prevalence rates of gastrointestinal diseases such as cancer. In Korea, with every 39.6 persons per 100,000 suffering from cancer, Mongolia with 33.1 per 100,000, and Japan with 27.5 per 100,000 ranked as 1, 2, and 3 respectively. Due to the rising prevalence of GI diseases, developing countries are experiencing high demand for minimally invasive surgical procedures, increasing the demand for endoscopy devices. Regulatory changes are likely to increase costs related to new product development and service offerings to clients. These changes are related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes. For instance, according to Dr. Fazal data 2020, 92% of working at an enterprise (over 1,000 employees) expect GDPR compliance to cost their business over $50,000. About 44% of the companies spend more than $50,000 and about 10% spend over a million dollars. according to a report by Ernst and Young (EY), Fortune 500 companies are spending $7.8 billion to comply with GDPR. The GDPR is an EU law on the data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). It also regulates the export of personal data outside the EU and EEA areas. Additionally, the FDA is requesting more clinical data to support claims, therefore increasing the time to process 510(k) by over 55% over the last decade. The potential loss of revenue due to delay in product release and additional costs incurred due to stringent approval processes puts strain on investments relating to new product development, thereby affecting the growth of the market. Companies in the endoscopy devices and equipment market are increasingly developing endoscopy robotic systems as they are more flexible, effective than conventional endoscopy devices. These robotic endoscopy devices help in eliminating difficulties in therapeutic endoscopy, expanding endoscopy’s vision and reach, reducing labor intensity, improving communication, reach, vision, control, and the ability to perform an endoscopy. These devices are used in gastrointestinal surgeries, urology/gynecology surgeries, ENT surgeries, cardiovascular surgeries, neuro/spinal surgeries, laparoscopy surgeries, and arthroscopy surgical applications. In 2021, Fujifilm partnered with SMART Medical Systems for developing a next-generation solution for colon endoscopy, the G-EYE 700-series endoscope system. The unique innovation offers exceptional visualization capabilities and outstanding quality of diagnostic images. Medicines and Healthcare products Regulatory Agency(MRHA), a regulatory body for medical devices of the UK, is a regulatory body governing drug and device alerts, drug safety updates, blood regulation, and safety, marketing authorizations and licensing guidance, medical devices regulation, and safety and many other activities. According to safety guidelines by MRHA, the medical device manufacturing companies in the industry recall their medical devices if any problem or defect is detected. For instance, in April 2022, KARL STORZ, a German endoscopy device company, issued urgent medical device recall notice for certain KARL STORZ flexible endoscopes after it detected issues in product description and instructions for use and potential risk of injury during the use of the device. Major players in the endoscopy devices and equipment market are Olympus Corporation, Fujifilm, Boston Scientific Corporation, Conmed Corporation, Stryker Corporation, Smith & Nephew PLC., KARL STORZ GmbH & Co. KG, Hoya Corporation, Johnson & Johnson, and Ethicon. North America was the largest region in the global endoscopy devices and equipment market in 2022. Asia-Pacific was the second largest market in endoscopy devices and equipment market. The regions covered in the global endoscopy devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the vision care devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The endoscopy devices and equipment market consist of sales of instruments such as biopsy forceps, trocar sleeves, tissue scissors and cutters, burs, cleaning brushes, tube sets (inflow and outflow), tissue staplers, ligation devices, and suturing systems. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global endoscopy devices and equipment market is segmented - 1) By Product: Endoscope, Endoscopy Operative Devices , Endoscopy Visualization Systems 2) By Application: Bronchoscopy, Arthroscopy, Laparoscopy, Urology endoscopy, Neuroendoscopy, Gastrointestinal endoscopy, Obstetrics/gynecology endoscopy, ENT endoscopy, Other Applications 3) By End-User: Hospitals, Clinics, Other End Users

Medical equipment maintenance refers to a set of activities conducted to keep the equipment in working condition. Medical equipment needs to be maintained in working order and periodically calibrated for the effectiveness and accuracy of the results. The main types of services in medical equipment maintenance are preventive maintenance, corrective maintenance, and operational maintenance. Preventive maintenance is the process of maintaining equipment and assets regularly to keep them working and avoid costly unplanned downtime due to unexpected equipment breakdowns. The different technologies include multi-vendor OEMS, single-vendor OEMs, independent service organization, and in-house maintenance and involve various devices such as imaging equipment, endoscopic devices, surgical instruments, and electro-medical equipment. It is implemented in various areas such as hospitals, diagnostic imaging centers, dialysis centers, ambulatory surgical centers, dental clinics, and specialty clinics, among others. The medical equipment maintenance market research report is one of a series of new reports from The Business Research Company that provides medical equipment maintenance market statistics, including the medical equipment maintenance industry global market size, regional shares, competitors with a medical equipment maintenance market share, detailed medical equipment maintenance market segments, market trends and opportunities, and any further data you may need to thrive in the medical equipment maintenance industry. This medical equipment maintenance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global medical equipment maintenance market size grew from $32.55 billion in 2022 to $37.31 billion in 2023 at a compound annual growth rate (CAGR) of 14.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The medical equipment maintenance market size is expected to grow to $56.03 billion in 2027 at a CAGR of 10.7%. The increase in demand for medical devices is significantly contributing to the growth of the medical equipment maintenance market. Medical devices are instruments, machines, and apparatus that are used for medical purposes to prevent, diagnose, or treat diseases. The rising demand for medical devices requires effective medical equipment maintenance services to lower dispatch costs, minimize patient dissatisfaction, ensure prompt patient treatment, and lower fatality and risk during patient care. For instance, according to the International Trade Administration and U.S. Department of Commerce report, the total production of medical devices and equipment in India reached $4,473 million in 2020, which is an increase compared to $2,390 million in 2019. Therefore, the increase in demand for medical devices is expected to propel the growth of the medical equipment maintenance market going forward. Strategic partnerships and collaborations are shaping the medical equipment maintenance market. For instance, in February 2021, Siemens Healthineers, a Germany-based medical technology company, and the Kantonsspital Baden (KSB), a Switzerland-based hospital formed a technological and strategic partnership for eight years. This partnership aims to help Kantonsspital Baden to expand its capabilities, optimize business processes, and advance innovation. It includes maintenance of medical imaging systems, technology needs, and capacity assessment, holistic technology management, process optimization, expansion of telemedicine solutions, and certified employee training programs. Additionally, in March 2021, Agiliti, a US-based medical equipment management company acquired Northfield Medical, a US-based company that offers repairing and maintenance services for surgical instruments for $475 million. Through this acquisition, Northfield Medical offers medical device care and repair, with a focus on surgical instruments, endoscopes, and other operating room equipment. In March 2021, Fujifilm Healthcare, a Japan-based diagnostics imaging systems company, acquired Hitachi’s diagnostic imaging-related business for an amount of $1.52 billion (€1.3 billion). Through this acquisition, Fujifilm aims to expand its diagnostic products and services business globally to offer comprehensive solutions for clinical needs. Hitachi Ltd. is a Japan-based company that manufactures medical equipment and provides medical equipment maintenance services. Major players in the medical equipment maintenance market are GE Healthcare, Siemens Healthineers, Koninklijke Philips N.V., Medtronic PLC., FUJIFILM Holdings Corporation, Canon Inc., Carestream Health Inc., Dräger, Toshiba International Corporation, Althea Group, Olympus Corporation, B. Braun Melsungen AG, KARL STORZ GmbH & Co. KG, Aramark Services Inc., and Johnson & Johnson. North America was the largest region in the medical equipment maintenance market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medical equipment maintenance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the medical equipment maintenance market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The medical equipment maintenance market consists of revenues earned by entities that are engaged in the service of preventive maintenance, periodic inspection, and corrective maintenance of medical equipment. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global medical equipment maintenance market is segmented - 1) By Service Type: Preventive Maintenance, Corrective Maintenance, Operational Maintenance 2) By Device: Imaging Equipment, Endoscopic Devices, Surgical Instruments, Electro-medical Equipment 3) By Technology: Multi-Vendor OEMs, Single-Vendor OEMs, Independent Service Organization, In-House Maintenance 4) By End User: Hospital, Diagnostic Imaging Centres, Dialysis Centres, Ambulatory Surgical Centres, Dental Clinics And Speciality Clinics, Other End Users

Medication adherence are the systems that helps to check if a person follows medication recommended by a healthcare provider, whether patients take their medications as prescribed, as well as whether they continue to take a prescribed medication. Medication adherence hardware and software help medical personnel with the patient’s intake to prescribed medication to reduce cases of worsening disease and deaths and decrease healthcare costs. The main types of medication adherence are hardware-centric and software-centric. Medication adherence products that are software-centric are a collection of programmes or applications which monitor, record, and notify the individual and his or her caregiver about their medication compliance. The different medications include cardiovascular, central nervous system, diabetes, oncology, respiratory, gastrointestinal, rheumatology, others and are used in various applications such as hospital, retail pharmacies, long-term care facilities, mail-order pharmacies. The medication adherence market research report is one of a series of new reports from The Business Research Company that provides medication adherence market statistics, including medication adherence industry global market size, regional shares, competitors with a medication adherence market share, detailed medication adherence market segments, market trends and opportunities, and any further data you may need to thrive in the medication adherence industry. This medication adherence market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global medication adherence market size will grow from $3.18 billion in 2022 to $3.58 billion in 2023 at a compound annual growth rate (CAGR) of 12.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global medication adherence market size is expected to grow to $5.36 billion in 2027 at a CAGR of 10.6%. The increasing requirement for medication adherence solutions to overcome poor adherence to prescribed medication in the healthcare industry is projected to boost the demand for medication adherence solutions. According to a study published by The Journal of Allergy and Clinical Immunology, in Practice, there has been an increase in controller inhaler use between January and March 2020 by 14.5% where, Propeller Health, a digital platform that tracks the inhaler consumption was used to send alerts to the patients when it is missed. Non-adherence to medication increases cost urging the patients to use medication adherence to treat the problem effectively, thereby generating higher demand for medication adherence solutions. Inadequate healthcare infrastructure in developing countries is predicted to hinder the growth of the medication adherence market. In September 2021, according to a United Nations report, the health system in Afghanistan is in danger of collapsing, while on the streets of Kabul, the hunger that families are experiencing is just as severe there as it is in the country's drought-stricken rural districts. Moreover 9 out of 37 COVID-19 hospitals were closed. The poor infrastructure wedges the gap between the patient and the system restraining the growth of the medication adherence market. Major players are undertaking strategic initiatives such as partnerships and business expansions in untapped regions, which is likely to be a major trend in the medication adherence market. For instance, In December 2021, AdhereHealth, a US-based healthcare technology company specialising in medication adherence insights and health outcomes, partnered Hero. The partnership aimed at using Hero's digital in-home care platform to assist patients with chronic illnesses that have high costs, high risks, and complicated medication regimens. Hero is a medication adherence company that delivers end-to-end medication management service for patients and caregivers. In November 2021, CareDx, Inc., a US-based precision medicine company, acquired MedActionPlan for an undisclosed amount. The acquisition aimed to contribute to CareDx's mission of linking transplant patient offerings. MedActionPlan is a US-based company providing medication adherence services. Major players in the medication adherence market are Koninklijke Philips N.V., Cardinal Health Inc., Omnicell Inc., McKesson Corporation, Johnson & Johnson Services, Inc., Proteus Digital Health, Inc., AdhereTech Inc., Qualcomm Incorporated, Adherence Solutions LLC and SMRxT Inc. North America was the largest region in the medication adherence market in 2022. Western Europe was the second largest region in the global medication adherence market. The regions covered in the global medication adherence market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the medication adherence market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. Medication adherence market consists of sales of instruments such as smart pill bottles, smart caps, smart medical watches, wearable sensors and others. The market also includes technology associated applications such as cloud-based databases, health programs, patient web portals, mobile medication management applications and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global medication adherence market is segmented - 1) By Type: Hardware Centric, Software Centric 2) By Medication: Cardiovascular, Central Nervous System, Diabetes, Oncology, Respiratory, Gastrointestinal, Rheumatology, Other Medications 3) By Application: Hospital, Retail Pharmacies, Long-Term Care Facilities, Mail-Order Pharmacies

Dialysis devices and equipment are used to filter a patient’s blood by removing waste products such as urea, creatinine, and excess water when kidneys fail or are damaged, dysfunctional, or missing. The main products of dialysis devices and equipment are hemodialysis devices and peritoneal dialysis devices. Hemodialysis is a process where a dialysis machine and a special filter called an artificial kidney, or a dialyzer, are used to clean the blood. The various applications involved are serum and blood treatment, virus purification, drug binding studies, and others. The various end-users are hospitals, clinics, ambulatory surgical centres, and home care settings. The dialysis devices and equipment market research report is one of a series of new reports from The Business Research Company that provides dialysis devices and equipment market statistics, including dialysis devices and equipment industry global market size, regional shares, competitors with a dialysis devices and equipment market share, detailed dialysis devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the dialysis devices and equipment industry. This dialysis devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global dialysis devices and equipment market size will grow from $4.72 billion in 2022 to $5.01 billion in 2023 at a compound annual growth rate (CAGR) of 6.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The dialysis devices and equipment market size is expected to grow to $6.12 billion in 2027 at a CAGR of 5.1%. The increasing prevalence of kidney failure is driving the market for dialysis devices and equipment. The main purpose of dialysis devices and equipment is to artificially filter the blood to get rid of any toxins in the blood and to prevent such waste products from reaching hazardous levels. Chronic kidney disease (CKD) is a condition in which the kidneys are damaged and cannot filter the blood. According to the National kidney Foundation, in 2021, kidney disease affects 37 million people in the US and 90% of the patients are unaware about it. 2 in 5 adults who had serious kidney disease didn’t know that they had it. Product recalls have been the major restraint in the dialysis devices and equipment market. Product recalls are actions taken by organizations or any regulatory authority like US FDA to remove a product or device from the market. The dialysis devices and equipment are removed from the market when they fail to perform the functions for which they were manufactured. For example, B. Braun Medical Inc. recalls Dialog hemodialysis systems due to defective conductivity sensors. This machine is used in the treatment of chronic kidney disease for patients whose kidneys are no longer healthy enough to filter the blood to get rid of the wastes and excess fluid. Similarly, the Dialyzer, a device by the Fresenius Medical Care group was recalled due to the invalid message shown on the equipment when the Sustained low-efficiency Dialysis (SLED) program is used. The latest trend in the dialysis devices and equipment market is the use of technology to develop innovative products that can enhance functionality. To enhance the quality of the devices, new methods are being developed to speed up the process of filtering the blood and improve the overall filtration process. As a result of improved technology products like Revaclear High-Flux Dialyzer by Baxter, which enhances the filtration process of the blood by improving the speed at which the blood is filtered are being developed. Revaclear dialyzers are devices that can help detect renal failure by hemodialysis. With the improvement in technology, innovations in the devices are expected to continue. In April 2022, Baxter International received FDA clearance for its ST Set in-hospital dialysis machine. The company had filed an emergency use authorization request back in August 2020. Such approvals by FDA positively impact the global dialysis devices market. In September 2022, W.L. Gore & Associates, a US-based material science company, acquired InnAVasc Medical for an undisclosed amount. The acquisition strengthens the company’s ambition to improve the patients’ lives and providing innovative treatment to them. InnAVasc is a US-based medical technology company developing treatment to ease the dialysis patients. Major players in the dialysis devices and equipment market are Fresenius Medical Care AG & Co. KGaA, Baxter International, Nikkiso Co. Ltd., DaVita Inc., B. Braun Avitum AG, NxStage Medical, Asahi Kasei Corporation, Diaverum Deutschland GmbH, Medivators Inc., and Nipro Corporation. Asia-Pacific was the largest region in the global dialysis devices and equipment market in 2022. North America was the second largest market in dialysis devices and equipment market. The regions covered in the global dialysis devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the dialysis devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The dialysis devices and equipment market consist of sales of instruments such as dialyzers, dialysis pumping machines, blood pumps, catheters, and tubing kits that are used for dialysis. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global dialysis devices and equipment market is segmented - 1) By Product: Hemodialysis Devices, Peritoneal Dialysis Devices 2) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings 3) By Application: Serum And Blood Treatment, Virus Purification, Drug Binding Studies, Other Applications

Hemodialysis and peritoneal dialysis are used to eliminate waste products and excess fluids such as urea and creatinine from the blood by redirecting blood to a machine for the cleaning process. Hemodialysis refers to a treatment in which the blood is cleaned using a dialysis machine and a specific filter known as an artificial kidney, or dialyzer. It is a type of dialysis that uses the patient's own bodily tissues inside the abdominal cavity as a filter.  The main types of hemodialysis and peritoneal dialysis are hemodialyses, short-term catheters, chronic catheters, graft, fistula, and peritoneal dialysis. Hemodialysis refers to a procedure where a dialysis machine and a special filter called an artificial kidney, or a dialyzer, are used to clean the blood. The modality is conventional and daily (day time, night time). The end-users involved are hospitals, clinics, dialysis centers, and home dialysis. The hemodialysis and peritoneal dialysis market research report is one of a series of new reports from The Business Research Company that provides hemodialysis and peritoneal dialysis market statistics, including hemodialysis and peritoneal dialysis industry global market size, regional shares, competitors with a hemodialysis and peritoneal dialysis market share, detailed hemodialysis and peritoneal dialysis market segments, market trends and opportunities, and any further data you may need to thrive in the hemodialysis and peritoneal dialysis industry. This hemodialysis and peritoneal dialysis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hemodialysis and peritoneal dialysis market size grew from $73.86 billion in 2022 to $80.17 billion in 2023 at a compound annual growth rate (CAGR) of 8.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hemodialysis and peritoneal dialysis market size is expected to grow to $110.29 billion in 2027 at a CAGR of 8.3%. The growing prevalence of kidney diseases is expected to propel the growth of the hemodialysis and peritoneal dialysis market going forward. Kidney disorders refer to a heterogeneous group of disorders that affect the structure and function of the kidney. Advanced chronic renal disease can result in dangerously high amounts of fluid, electrolytes, and wastes in the body, hemodialysis and peritoneal dialysis are used in the treatment in which the blood is cleaned using a dialysis machine and a specific filter known as an artificial kidney. For instance, in 2021, according to the Centers for Disease Control and Prevention’s report on chronic kidney disease, a US-based national public health agency, around 15% of US adults, or 37 million people, are estimated to have chronic kidney diseases. Therefore, the growing prevalence of kidney diseases is driving the hemodialysis and peritoneal dialysis market. Technological advancements are a key trend gaining popularity in hemodialysis and peritoneal dialysis. Major companies operating in the hemodialysis and peritoneal dialysis market are focused on developing new technological solutions to strengthen their position. For instance, in April 2022, Kuleana Technology, Inc., a Seattle-based startup focused on improving renal replacement therapies, got the first dialysis funding from the National Kidney Foundation (NKF) Innovation Fund. Kuleana is creating revolutionary portable hemodialysis equipment that does not need to be connected to an external water supply and won't need complicated sorbents. Due to the ability to dialyze while on the go, this device will be more efficient than existing dialysis, enabling whenever and wherever dialysis for millions of patients globally. In March 2021, DaVita Kidney Care, a US-based company that treats patients with chronic kidney failure and end-stage kidney disease, extended in collaboration with Fresenius Medical Care. The collaboration offers DaVita patients home hemodialysis technology across the United States, including NxStage machines, supplies, and a connected health platform. The cooperation helps both businesses achieve their objectives of encouraging more patients to select home dialysis, which can improve the quality of life for those with chronic kidney failure. Fresenius Medical Care is a US-based company specializing in kidney care. Major players in the hemodialysis and peritoneal dialysis market are Baxter International Inc., Nipro Corporation, B Braun Melsungen AG, Nikkiso Co. Ltd., Becton Dickinson And Company, Medtronic PLC, Asahi Kasei Corp., DaVita Inc., Diaverum, Cook Group Incorporated, Angiodynamics, Toray Medical Co. Ltd., Drägerwerk AG And Co. KGAA, and Cantel Medical Corporation. North America was the largest region in the hemodialysis and peritoneal dialysis market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemodialysis and peritoneal dialysis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the hemodialysis and peritoneal dialysis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The hemodialysis and peritoneal dialysis market includes revenues earned by entities by n-centerhemodialysis, home hemodialysis, and peritoneal dialysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.  The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global hemodialysis and peritoneal dialysis market is segmented - 1) By Type: Hemodialysis, Short-Term Catheter, Chronic Catheter, Graft, Fistula, Peritoneal Dialysis 2) By Modality: Conventional, Daily (Day Time, Night Time) 3) By End User: Hospitals, Clinics, And Dialysis Centers, Home Dialysis